Penumbra Q2 Earnings Beat Estimates; Raises FY21 Sales Outlook

  • Penumbra Inc PEN reported Q2 sales of $184.3 million, an increase of 75.3% Y/Y, or 72.7% on a constant currency basis, beating the consensus of $170.76 million.
  • Revenue from sales of vascular products grew to $100.7 million, +117.6%, or 115.8% on a constant currency basis. 
  • Revenue from sales of neuro products increased to $83.6 million +42.0% or 38.8% on a constant currency basis.
  • The gross margin improved to 64.4%, up from 61.8% a year ago.
  • Penumbra posted an operating income of $10.3 million compared to an operating loss of $17.6 million in Q2 FY20.
  • The Company posted an adjusted EPS of $0.21, surpassing the estimate of $0.17, and a turnaround from an EPS loss of $(0.30).
  • FY21 Guidance: Penumbra increased its sales guidance to $720 million - $730 million, compared to $695 million - $705 million, expected previously.
  • BTIG maintained a Buy rating on Penumbra and raised the price target to $308.
  • Price Action: PEN shares closed at $258.39 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CarePrice TargetReiterationAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!